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A brief look at AMD and developments which have
completely subverted the therapeutic approach to
patients affected by this disease.
New therapies available include: monoclonal antibody
inhibitors of VEGF (Peptaganib, Bevacizumab, Ranibizu-
mab) with the protocols currently in use and a brief
reference to new anti-angiogenic therapies that include:
decoy of VEGF receptor (VEGF Trap, Small Interfering
RNA based therapies, Bevasiranib and AGN211745,
Sirolimus) and the VEGF cascade of tyrosine kinase
inhibitors (Vatalanib, Pazopanib, TG100801, TG101095,
AG013958 and AL39324).
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